Denali continues decline after Sanofi ALS study failure
The Fly

Denali continues decline after Sanofi ALS study failure

Denali Therapeutics (DNLI) disclosed Friday morning that it was informed by its strategic partner Sanofi (SNY) that the Phase 2 HIMALAYA study evaluating SAR443820/DNL788 in participants with amyotrophic lateral sclerosis did not meet the primary endpoint of change in ALS Functional Rating Scale-Revised. SAR443820/DNL788 is an investigational oral brain-penetrant RIPK1 inhibitor being co-developed by Sanofi and Denali. Sanofi will continue to conduct the K2 Phase 2 study of SAR443820/DNL788 in participants with multiple sclerosis, Denali adds. Shares of Denali are down 2% to $16.65 in premarket trading.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on DNLI:


Price Change
S&P 500
Dow Jones
Nasdaq 100

Popular Articles